Atox looks towards 3Q20 NDA submission for necrotizing infection candidate following Phase III readout

Following its Phase III readout in necrotizing soft tissue infection, 17-year-old Atox is looking to bring lead product reltecimod to market, with plans to submit an NDA this quarter under the accelerated approval pathway.

The company reported data on Thursday in the Annals of Surgery from its pivotal ACCUTE trial showing reltecimod led to an improvement on a clinical composite endpoint in patients with necrotizing soft tissue infections (NSTIs). ...